



**Consolidated Financial Statements for the First Quarter Ended June 30, 2021
FY2022 (April 1, 2021 – June 30, 2021) [UNAUDITED]**

August 3, 2021

Company name: Takara Bio Inc.
 Stock exchange listings: Tokyo Stock Exchange (1st section)
 Code number: 4974
 URL: <https://www.takara-bio.co.jp>
 Company representative: Koichi Nakao, President
 Contact: Takuya Kakemi, Executive Officer, President of Corporate Management Division
 Tel. (077) 565-6970

Scheduled date of quarterly statement filing: August 6, 2021

Scheduled date of starting delivery of dividends: -

Supplementary documents of the financial results: Yes

Financial results information meeting: No

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.

2. Amounts are rounded down to the nearest million yen.

1. Results for the three months ended June 30, 2021 (Apr. 1, 2021 – Jun. 30, 2021)

(1) Consolidated operating results

	(Percentages indicate changes from the same period of the previous fiscal year.)			
	Three months ended Jun. 30, 2021		Three months ended Jun. 30, 2020	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	15,272	220.1	6,938	(19.8)
Operating profit	8,504	-	693	(69.2)
Ordinary profit	8,579	-	745	(66.1)
Net income (loss) attributable to owners of parent	6,025	-	404	(74.6)
Net income per share (in yen)	50.04		3.36	
Fully diluted net income per share (in yen)	-		-	
(Note) Comprehensive income	8,210	(-%)	(48)	(-%)

(2) Consolidated financial position

	As of Jun. 30, 2021	As of Mar 31, 2021
	(Millions of yen)	(Millions of yen)
Total assets	99,658	89,750
Net assets	80,586	74,302
Equity ratio (%)	80.7	82.7
Net assets per share (in yen)	668.01	616.05
(Reference) Equity	80,438	74,181

2. Dividends

	Annual dividends per share in yen		
	Year ended Mar. 31, 2021	Year ended Mar. 31, 2022	Year ending Mar. 31, 2022 (Forecast)
First quarter end	-	-	-
Second quarter end	0.00	-	0.00
Third quarter end	-	-	-
Year end	16.00	-	20.00
Annual	16.00	-	20.00

(Note) Revision of dividend payment forecast since the most recently announced payment forecast: Yes

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)

3. Forecast for the year ending March 31, 2022 (Apr. 1, 2021 – Mar. 31, 2022)

(Percentages indicated changes from the same period of the previous fiscal year.)

	Six months ending		Year ending	
	Sep. 30, 2021		Mar. 31, 2022	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	29,700	70.8	54,200	17.6
Operating profit	11,400	205.1	17,000	21.8
Ordinary profit	11,400	198.4	17,100	20.8
Net income attributable to owners of the parent	7,900	247.3	11,900	24.6
Net income per share (in yen)	65.61		98.82	

[Note] Revision of financial forecast since the most recently announced payment forecast: Yes

※ Others

(1) Changes in subsidiaries during the three months ended June 30, 2021

(Changes in specified subsidiaries resulting in change of scope) : No

Newly included: – (Name)

Excluded: – (Name)

(2) Application of special accounting methods to the consolidated quarterly financial statements: No

(3) Changes in accounting policies, changes in accounting estimates, and retrospective restatement

1) Changes based on revisions of accounting standard: Yes

2) Changes other than ones based on revisions of accounting standard: No

3) Changes in accounting estimates: No

4) Restatement: No

NOTE: For details, please refer to "(4) Notes to Consolidated Quarterly Financial Statements (Changes in Accounting Policies)" of "2. Consolidated Quarterly Financial Statements and Primary Notes" on page 9 of the attached material.

(4) Number of outstanding shares (Common stock)

1) Number of outstanding shares at year end (Treasury stocks are included)

As of June 30, 2021 120,415,600

As of March 31, 2021 120,415,600

2) Number of treasury stocks at year end

As of June 30, 2021 -

As of March 31, 2021 -

3) Average number of outstanding shares

As of June 30, 2021 120,415,600

As of June 30, 2020 120,415,600

※ These quarterly financial statements are not subject to auditing.

※ Comment regarding appropriate use of earnings forecasts and other special notes

Forward-looking statements contained in this document are determined by the Takara Bio Company based on information currently available to the Company and include a number of uncertainties. Actual results could differ from these forecasts due to changes in conditions that occur in the future. For information regarding the above, please refer to 1. Qualitative Information for the three months ended June 30, 2021 (4) Qualitative Information Regarding Consolidated Forecasts on page 2 of the attached document.

Contents of the attached document

1. Overview of Financial Results for the three months ended June 30, 2021.....	2
(1) Overview of Financial Results.....	2
(2) Overview of Financial Position.....	2
(3) Overview of Cash Flows.....	2
(4) Qualitative Information Regarding Consolidated Forecasts.....	2
2. Consolidated Quarterly Financial Statements and Primary Notes.....	4
(1) Consolidated Quarterly Balance Sheets.....	4
(2) Consolidated Quarterly Statements of Profit or Loss and Consolidated Quarterly Statements of Comprehensive Income.....	6
(Consolidated Quarterly Statements of Profit or Loss)	
(For the Three Months Ended June 30, 2021).....	6
(Consolidated Quarterly Statements of Comprehensive Income)	
(For Three Months Ended June 30, 2021).....	7
(3) Consolidated Quarterly Statements of Cash Flow	8
(4) Notes to Consolidated Quarterly Financial Statements.....	9
(Notes on Premise of Going Concern)	9
(Notes in case of Changes in Marked Amount of Shareholders' Equity).....	9
(Changes in Subsidiaries during the three months ended June 30, 2021)	9
(Changes in Accounting Policies)	9
(Additional Information).....	9
(Segment Information).....	9
(Significant Subsequent Events)	9
3. Supplementary Information.....	10
(1) Trends in Key Indicators for Business Management.....	10
(2) Comparative Consolidated Statement of Income	11
(3) Comparative Statement of Profit Relating to Consolidated Earnings Forecast.....	12

1. Overview of Financial Results for the three months ended June 30, 2021

(1) Overview of Financial Results

The outlook for the global economy in the first quarter of the current fiscal year is uncertain due to the prolonged trade friction between the U.S. and China and the impact of the new Coronavirus disease (COVID-19).

Against these circumstances, Takara Bio (the Group) is promoting the initiatives to advance the development of fundamental bio-drug discovery technologies and become a drug discovery company that continuously creates new modalities through the reagents, instruments and the CDMO business under the six-year Long-Term Management Plan FY2026, which ends in fiscal 2026, and the three-year Medium-Term Management Plan 2023, which ends in fiscal 2023¹.

In the first quarter of the fiscal year under review, although the sales of Gene Therapy decreased year on year, the sales of Reagents, Instruments, and CDMO increased year on year. In Reagents and Instruments, PCR testing-related products for the new Coronavirus contributed to the increase. As a result, net sales increased to ¥15,272 million (220.1% compared with the same period of the previous fiscal year). The cost of sales decreased to ¥2,133 million (95.5% compared to the same period of the previous fiscal year) due to a change in the sales mix and an improvement in the production utilization rate. As a result, gross profit increased to ¥13,138 million (279.3% compared to the same period of the previous fiscal year). Selling, general and administrative (SG&A) expenses amounted to ¥4,633 million (115.6% compared with the same period of the previous fiscal year), mainly due to an increase in personnel expenses and R&D expenses. Operating income increased to ¥8,504 million (1225.5% compared with the same period of the previous fiscal year).

As a result of the increase in operating income, ordinary income increased 1150.8% to ¥8,579 million, income before income taxes and minority interests increased to 1162.3% to ¥8,561 million, and net income attributable to owners of the parent increased 1491.0% to ¥6,025 million.

Since the Group is a single segment, the description by segment is omitted.

(2) Overview of Financial Position

Total assets at the end of the first quarter under review were ¥99,658 million, an increase of ¥9,907 million from the end of the previous fiscal year. This was mainly due to an increase of ¥5,492 million in cash and deposits, and an increase of ¥3,151 million in property, plant and equipment resulting from interior finishing work of Takara Bio USA, Inc.'s new office buildings and our acquisition of manufacturing facilities.

Total liabilities at the end of the first quarter of the current fiscal year were ¥19,071 million, an increase of ¥3,623 million from the end of the previous fiscal year. This was mainly due to an increase of ¥4,385 million in other current liabilities and a decrease of ¥761 million in income taxes payable.

Total net assets at the end of the first quarter under review were ¥80,586 million, an increase of ¥6,283 million from the end of the previous fiscal year. This was mainly due to an increase of ¥4,099 million in retained earnings and an increase of ¥2,145 million in foreign currency translation adjustments due to the yen's depreciation.

(3) Overview of Cash Flows

Net cash provided by operating activities amounted to ¥5,604 million, an increase of ¥2,193 million from the same period of the previous fiscal year. This was mainly due to the balance of cash inflow and outflow. Cash inflow were from income before income taxes and minority interests of ¥8,561 million and depreciation and amortization of ¥808 million. Cash outflow were from income taxes paid of ¥3,105 million and a decrease in other current liabilities of ¥948 million.

Net cash provided by investing activities was ¥2,403 million, an increase of ¥3,178 million from the same period of the previous fiscal year, mainly due to purchase of property, plant and equipment and intangible assets of ¥2,241 million, proceeds from withdrawal of time deposits of ¥1,357 million, and proceeds from subsidy receipts of ¥3,349 million.

Net cash used in financing activities amounted to ¥1,881 million, an increase of ¥936 million from the same period of the previous fiscal year, mainly due to cash dividends paid of ¥1,846 million.

As a result of the above, the balance of cash and cash equivalents at the end of the first quarter of the current fiscal year, including the effect of exchange rate changes on cash and cash equivalents, increased by ¥6,656 million from the end of the previous fiscal year to ¥29,965 million.

(4) Qualitative Information Regarding Consolidated Forecasts

The earnings forecast announced in the financial results summary on May 13, 2021 has been revised. For details, please refer to "Notice of Revision of Financial Forecast and Dividend (Dividend Increase)" announced today (August 3, 2021).

For a comparison of the revised consolidated earnings forecasts with the results of the previous fiscal year and the previous

¹ FY2026 and FY2023 refer to the fiscal year ending March 2026 and 2023, respectively.

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)

earnings forecasts, please refer to the "Comparative Statement of Profit Relating to Consolidated Earnings Forecasts" on page 12 and later.

2. Consolidated Quarterly Financial Statements and Primary Notes

(1) Consolidated Quarterly Balance Sheets

(Millions of yen)

	As of Mar. 31, 2021	As of Jun. 30, 2021
Assets		
Current assets		
Cash and deposits	25,993	31,486
Notes and accounts receivable-trade	12,626	12,867
Merchandise and finished goods	4,966	4,943
Work in process	1,316	1,703
Raw materials and supplies	2,901	3,256
Other	1,352	1,320
Allowance for doubtful accounts	(41)	(39)
Total current assets	49,115	55,537
Non-current assets		
Property, plant and equipment		
Buildings and structures	15,670	16,281
Accumulated depreciation	(5,147)	(5,465)
Buildings and structures, net	10,522	10,815
Machinery, equipment and vehicles	7,058	7,554
Accumulated depreciation	(3,760)	(4,031)
Machinery, equipment and vehicles, net	3,297	3,523
Tools, furniture and fixtures	7,673	8,119
Accumulated depreciation	(5,141)	(5,402)
Tools, furniture and fixtures, net	2,531	2,716
Land	8,143	8,312
Construction in progress	3,756	6,043
Others	1,796	1,837
Accumulated depreciation	(282)	(330)
Others, net	1,514	1,506
Total Property, plant and equipment	29,766	32,918
Intangible assets		
Goodwill	6,149	6,451
Other	3,224	3,292
Total intangible assets	9,373	9,743
Investments and other assets		
Investments and other assets	1,495	1,458
Total investments and other assets	1,495	1,458
Total non-current assets	40,635	44,120
Total assets	89,750	99,658

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)

(Millions of yen)

	As of Mar. 31, 2021	As of Jun. 30, 2021
Liabilities		
Current liabilities		
Notes and accounts payable-trade	2,077	1,841
Accrued income taxes	3,146	2,384
Provision	739	985
Other	7,228	11,613
Total current liabilities	13,191	16,825
Non-current liabilities		
Retirement benefit liabilities	800	789
Other	1,456	1,456
Total non-current liabilities	2,256	2,246
Total liabilities	15,448	19,071
Net assets		
Shareholders' equity		
Share capital	14,965	14,965
Capital surplus	32,893	32,893
Retained earnings	27,085	31,185
Total shareholders' equity	74,945	79,044
Accumulated other comprehensive income		
Foreign currency translation adjustment	(529)	1,616
Cumulative remeasurements of retirement benefit	(234)	(222)
Total accumulated other comprehensive income	(763)	1,393
Non-controlling interests	120	148
Total net assets	74,302	80,586
Total liabilities and net assets	89,750	99,658

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)

(2) Consolidated Quarterly Statements of Profit or Loss and Consolidated Quarterly Statements of Comprehensive Income
(Consolidated Quarterly Statements of Profit or Loss)
(For the three months ended June 30, 2021)

(Millions of yen)

	Three months ended June. 30, 2020	Three months ended Jun. 30, 2021
Net sales	6,938	15,272
Cost of sales	2,234	2,133
Gross profit	4,703	13,138
SG&A expenses		
Employees' salaries and bonuses	1,044	1,211
Retirement benefit expenses	53	57
R&D expenses	1,172	1,294
Provision for doubtful accounts	150	191
Other	1,588	1,878
Total SG&A expenses	4,009	4,633
Operating profit	693	8,504
Non-operating profit		
Interest income	33	30
Foreign exchange gains	4	26
Rent income from real estate	30	32
Other	12	5
Total non-operating profit	81	94
Non-operating expenses		
Interest expenses	6	6
Rent expenses on real estate	9	12
Other	13	1
Total non-operating expenses	29	19
Ordinary profit	745	8,579
Extraordinary profit		
Gain on sale of fixed assets	-	0
National subsidies	-	49
Total extraordinary profit	-	49
Extraordinary losses		
Loss on disposal of fixed assets	8	17
Asset shrinkage losses	-	49
Total extraordinary losses	8	67
Profit before income taxes and others	736	8,561
Income taxes-current	226	2,462
Income taxes-deferred	99	55
Total income taxes	326	2,517
Net income	410	6,044
Net income attributable to non-controlling interest	6	18
Net income attributable to owners of the parent	404	6,025

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)

(Consolidated Quarterly Statements of Comprehensive Income)

(For the three months ended June 30, 2021)

(Millions of yen)

	Three months ended Jun. 30, 2020	Three months ended Jun. 30, 2021
Net income	410	6,044
Other comprehensive income		
Foreign currency translation adjustment	(467)	2,154
Remeasurements of retirement benefit	8	11
Total other comprehensive income	(458)	2,166
Comprehensive income	(48)	8,210
Comprehensive income attributable to:		
Owners of the parent	(48)	8,183
Non-controlling interest	0	27

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)

(3) Consolidated Quarterly Statements of Cash Flows

(Millions of yen)

	Three months ended Jun. 30, 2020	Three months ended Jun. 30, 2021
Net cash provided by (used in) operating activities		
Profit before income taxes and others	736	8,561
Depreciation and amortization	815	808
Depreciation and amortization on other	21	23
Amortization of goodwill	123	120
Increase (decrease) in allowance for doubtful accounts	1	(4)
Increase (decrease) in other provision	241	221
Increase (decrease) in retirement benefit liabilities	(0)	(11)
Interest income	(33)	(30)
Interest expenses	6	6
Loss (gain) on sale and retirement of fixed assets	8	17
Decrease (increase) in trade receivables-trade	2,130	(9)
Decrease (increase) in inventories	(787)	(379)
Increase (decrease) in notes and accounts payable-trade	83	(388)
Increase (decrease) in other current liabilities	494	(948)
Other	76	44
Subtotal	3,918	8,031
Interest and dividend income received	19	13
Income expenses paid	(6)	(6)
Income taxes paid	(520)	(3,105)
Subsidies received	-	671
Net cash provided by (used in) operating activities	3,411	5,604
Net cash provided by (used in) investing activities		
Payments into time deposits	(0)	(36)
Proceeds from withdrawal of time deposits	-	1,357
Purchase of property, plant and equipment and intangible assets	(652)	(2,241)
Proceeds from sales of property, plant and equipment and intangible assets	0	0
Purchase of other depreciable assets	(116)	(25)
Subsidies received	-	3,349
Other	(6)	(0)
Net cash provided by (used in) investing activities	(775)	2,403
Net cash provided by (used in) financing activities		
Dividends paid	(910)	(1,846)
Repayments of lease obligations	(34)	(34)
Net cash provided by (used in) financing activities	(944)	(1,881)
Effect of exchange rate change on cash and cash equivalents	(147)	530
Net increase (decrease) in cash and cash equivalents	1,543	6,656
Cash and cash equivalents at beginning of period	14,462	23,308
Cash and cash equivalents at end of period	16,006	29,965

(4) Notes to Consolidated Quarterly Financial Statements

(Notes on Premise of Going Concern)

No items to report.

(Notes in case of Changes in Marked Amount of Shareholders' Equity)

No item to report.

(Changes in Subsidiaries during the three months ended June 30, 2021)

From the first quarter of the current fiscal year, Takara Bio UK Ltd, newly established as a 100% subsidiary of Takara Bio Europe S.A.S. has been included in the scope of consolidation.

(Changes in Accounting Policies)

(Application of Accounting Standard for Revenue Recognition)

The Company adopted the "Accounting Standard for Revenue Recognition" (ASBJ Statement No. 29, March 31, 2020, hereinafter referred to as the "Accounting Standard for Revenue Recognition") from the beginning of the first quarter of the current fiscal year and recognized revenue when control of promised goods or services is transferred to customers in an amount that is expected to be received in exchange for those goods or services.

With regard to the application of the Accounting Standard for Revenue Recognition, in accordance with the transitional treatment stipulated in the provisions of paragraph 84 of the Accounting Standard for Revenue Recognition, the cumulative effect of retrospectively applying the new accounting policy prior to the beginning of the first quarter of the current fiscal year was added to or deducted from retained earnings at the beginning of the first quarter of the current fiscal year, and a new accounting policy was applied from the beginning balance of the current fiscal year.

As a result, there was no impact on the Company's profit and loss for the first quarter of the current fiscal year. In addition, there is no impact on the balance of retained earnings at the beginning of the fiscal year.

(Additional Information)

(Accounting Estimates for the Impact of the COVID-19)

No material changes have been made to the assumptions used in the previous fiscal year, including the future spread and timing of convergence of the COVID-19.

(Segment Information)

[Segment Information]

Since our group is a single segment, this information is omitted.

(Significant Subsequent Events)

Not applicable.

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)

3. Supplemental Information

(1) Trends in Key Indicators for Business Management

1) Cash Flows

(Millions of yen)

	Three months ended Jun. 30, 2020 (Apr. 1, 2020 – Jun. 30, 2020)	Three months ended Jun 30, 2021 (Apr. 1, 2021 – Jun. 30, 2021)	Year ended Mar. 31, 2021 (Apr. 1, 2020 – Mar. 31, 2021)
Cash flow from operating activities	3,411	5,604	13,943
Cash flow from investing activities	(775)	2,403	(3,778)
Cash flow from financing activities	(944)	(1,881)	(1,103)

2) Sales Breakdown by Region

(Millions of yen)

	Three months ended Jun. 30, 2020 (Apr. 1, 2020 – Jun. 30, 2020)	Three months ended Jun 30, 2021 (Apr. 1, 2021 – Jun. 30, 2021)	Year ended Mar. 31, 2021 (Apr. 1, 2020 – Mar. 31, 2021)
Japan	2,490	6,954	20,475
United States	1,992	2,247	7,862
China	1,126	3,094	8,415
Asia excluding Japan and China	450	1,748	4,917
Europe	788	1,170	3,743
Others	89	56	671
Total	6,938	15,272	46,086

(2) Comparative Consolidated Statement of Income

(Rounded down to one million yen)

	Three months ended Jun. 30, 2020	Three months ended Jun. 30, 2021	Y/Y change	Y/Y ratio
(Net sales)				
Reagents	5,515	12,873	7,358	233.4%
Instruments	166	390	224	234.9%
CDMO	1,137	1,955	817	171.9%
Gene therapy	119	53	(65)	44.7%
Total net sales	6,938	15,272	8,333	220.1%
(Operating profit and Loss)				
Net sales	6,938	15,272	8,333	220.1%
Cost of sales	2,234	2,133	(100)	95.5%
Gross profit	4,703	13,138	8,434	279.3%
SG & A expenses	4,009	4,633	624	115.6%
Transportation expenses	176	212	35	120.4%
Advertising expenses	20	13	(7)	65.2%
Promotion expenses	90	180	89	199.0%
R&D expenses	1,172	1,294	122	110.4%
Administrative expense, other	2,477	2,792	314	112.7%
Enterprise taxes (external standards taxation)	71	139	68	195.8%
Operating profit	693	8,504	7,810	1225.5%
(Non-operating income and Expenses)				
Non-operating income	81	94	13	116.7%
Non-operating expenses	29	19	(10)	65.5%
Ordinary profit	745	8,579	7,834	1150.8%
(Extraordinary income & Losses)				
Extraordinary income	-	49	49	-
Extraordinary losses	8	67	58	764.0%
Profit before income taxes and others	736	8,561	7,825	1162.3%
Income taxes	326	2,517	2,191	772.2%
Net income	410	6,044	5,633	1472.0%
Net income (loss) attributable to non-controlling interests	6	18	11	283.0%
Net income attributable to owners of the parent	404	6,025	5,621	1491.0%
Depreciation and amortization (Property, plant and equipment and intangible assets)	815	808	(7)	99.1%
Amortization of goodwill	123	120	(3)	97.4%

※1 From the first quarter of the current fiscal year, the names of the categories of net sales have been changed from "Research reagents", "Scientific instruments" and "Contract services" to "Reagents", "Instruments" and "CDMO".

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)

(3) Comparative Statement of Profit Relating to Consolidated Earnings Forecasts

1) First half ending Sep. 30, 2021

	First half ended Sep. 30, 2020	First half ending Sep. 30, 2021 Previous forecast	First half ending Sep.30, 2021 Current forecast	Y/Y Change	Y/Y Ratio	Previous forecast Change	Previous forecast Ratio
(Net sales)							
Reagents	13,336	19,128	24,058	10,721	180.4%	4,930	125.8%
Instruments	466	837	790	323	169.4%	(46)	94.4%
CDMO	3,373	4,033	4,727	1,353	140.1%	693	117.2%
Gene therapy	215	610	123	(92)	57.3%	(487)	20.3%
Total Net Sales	17,393	24,609	29,700	12,306	170.8%	5,090	120.7%
(Operating profit and Loss)							
Net sales	17,393	24,609	29,700	12,306	170.8%	5,090	120.7%
Cost of sales	5,565	7,948	8,749	3,183	157.2%	800	110.1%
Gross profit	11,827	16,661	20,950	9,123	177.1%	4,289	125.7%
SG & A expenses	8,090	9,521	9,550	1,459	118.0%	29	100.3%
Transportation expenses	336	441	425	89	126.7%	(16)	96.4%
Advertising expenses	31	41	29	(1)	94.2%	(12)	69.8%
Promotion expenses	276	398	434	158	157.5%	36	109.0%
R&D expenses	2,403	2,717	2,689	286	111.9%	(27)	99.0%
Administrative expenses, other	4,883	5,718	5,767	884	118.1%	49	100.9%
Enterprise taxes (external standards taxation)	160	203	203	42	126.2%	0	100.0%
Operating profit	3,736	7,139	11,400	7,663	305.1%	4,260	159.7%
(Non-operating income and Expenses)							
Non-operating income	143	114	135	(7)	94.7%	20	118.3%
Non-operating expenses	59	34	135	75	227.1%	101	397.9%
Ordinary profit	3,820	7,220	11,400	7,579	298.4%	4,180	157.9%
(Extraordinary income & Losses)							
Extraordinary income	1	2,888	2,992	2,990	-	104	103.6%
Extraordinary losses	539	2,905	3,021	2,482	560.3%	116	104.0%
Profit before income taxes and others	3,281	7,203	11,370	8,088	346.4%	4,167	157.9%
Income taxes	990	2,294	3,426	2,436	346.0%	1,132	149.3%
Net income	2,291	4,908	7,943	5,652	346.7%	3,035	161.8%
Net income (loss) attributable to non-controlling interests	16	18	43	26	256.3%	24	232.1%
Net income attributable to owners of parent	2,274	4,889	7,900	5,625	347.3%	3,010	161.6%
Depreciation and amortization (Property, plant and equipment and intangible assets)	1,631	1,727	1,736	104	106.4%	8	100.5%
Amortization of goodwill	246	236	245	(0)	99.6%	8	103.7%

※1 From the first quarter of the current fiscal year, the names of the categories of net sales have been changed from "Research reagents", "Scientific instruments" and "Contract services" to "Reagents", "Instruments" and "CDMO".

The original disclosure in Japanese was released on August 3, 2021 at 15:00 (GMT+8)

2) Year Ending Mar. 31, 2022

	Year ended Mar. 31, 2021 Actual	Year ending Mar. 31, 2022 Previous forecast	Year ending Mar. 31, 2022 Current forecast	Y/Y Change	Y/Y Ratio	Previous forecast Change	Previous forecast Ratio
(Net sales)							
Reagents	35,189	36,801	40,594	5,405	115.4%	3,793	110.3%
Instruments	1,726	1,720	1,542	(184)	89.3%	(178)	89.6%
CDMO	8,901	10,584	11,346	2,444	127.5%	761	107.2%
Gene therapy	268	1,393	716	448	267.0%	(676)	51.4%
Total Net Sales	46,086	50,500	54,200	8,113	117.6%	3,700	107.3%
(Operating profit and Loss)							
Net sales	46,086	50,500	54,200	8,113	117.6%	3,700	107.3%
Cost of sales	14,214	16,482	16,932	2,718	119.1%	449	102.7%
Gross profit	31,872	34,017	37,267	5,394	116.9%	3,250	109.6%
SG & A expenses	17,919	20,017	20,267	2,347	113.1%	250	101.2%
Transportation expenses	742	837	831	89	112.0%	(6)	99.3%
Advertising expenses	57	83	62	5	109.1%	(21)	74.6%
Promotion expenses	676	871	810	134	119.8%	(60)	93.0%
R&D expenses	5,545	5,812	6,003	457	108.3%	190	103.3%
Administrative expenses, other	10,496	12,003	12,128	1,632	115.6%	125	101.0%
Enterprise taxes (external standards taxation)	401	408	430	28	107.1%	21	105.3%
Operating profit	13,952	14,000	17,000	3,047	121.8%	3,000	121.4%
(Non-operating income and Expenses)							
Non-operating income	308	301	258	(49)	84.0%	(43)	85.7%
Non-operating expenses	101	101	158	57	156.9%	56	155.8%
Ordinary profit	14,159	14,200	17,100	2,940	120.8%	2,900	120.4%
(Extraordinary income & Losses)							
Extraordinary income	518	4,592	4,780	4,261	921.8%	187	104.1%
Extraordinary losses	1,125	4,651	4,849	3,724	430.9%	197	104.3%
Profit before income taxes and others	13,552	14,140	17,030	3,477	125.7%	2,889	120.4%
Income taxes	3,971	4,314	5,082	1,110	128.0%	767	117.8%
Net income	9,581	9,825	11,948	2,366	124.7%	2,122	121.6%
Net income (loss) attributable to non-controlling interests	34	25	48	14	141.4%	22	188.7%
Net income attributable to owners of parent	9,547	9,800	11,900	2,352	124.6%	2,100	121.4%
Depreciation and amortization (Property, plant and equipment and intangible assets)	3,220	3,653	3,687	467	114.5%	34	100.9%
Amortization of goodwill	486	473	473	(12)	97.4%	0	100.0%

※1 From the first quarter of the current fiscal year, the names of the categories of net sales have been changed from "Research reagents", "Scientific instruments" and "Contract services" to "Reagents", "Instruments" and "CDMO".